Schering's 'R&D Day' For Skeptical Analysts

Abrams, Sandra Lea
November 2005
Investment Dealers' Digest;11/7/2005, Vol. 71 Issue 42, p13
Trade Publication
The article reports that Schering-Plough has held what it called an "R&D day" for investment analysts at its Kenilworth, New Jersey, headquarters to inform them about its profit outlook for the next two years and prospects for new drugs. The pharmaceutical firm revealed that it plans to pursue in-licensing of drugs from other companies and acquisitions of other companies. However, drugs in the pipeline will only reach the commercial stage for at least another two or three years.


Related Articles

  • Merck and Schering-Plough Benefit From Joint Venture. Jarvis, Lisa // Chemical Market Reporter;1/31/2005, Vol. 267 Issue 5, p6 

    This article reports that Merck & Co. Inc. and Schering-Plough Corp. posted relatively solid fourth-quarter results, given the hardship each company has endured over the past two years. Both companies enjoyed a lift from the strong performance of their cholesterol drug joint venture, which...

  • Merck merger reshaping industry landscape. FITZGERALD, BETH // njbiz;3/16/2009, Vol. 22 Issue 11, p3 

    The article reports on the merger deal between Merck and Schering-Plough, two pharmaceutical companies both based in New Jersey. The deal worth $41.1 billion involved cash and stock transactions. With the merger, the companies promised to deliver new drugs, target high earnings growth and cost...

  • Schering-plough Chairman Says Earnings Are On Track Thus Far.  // Chemical Market Reporter;07/12/99, Vol. 256 Issue 2, p17 

    States that the earnings of Schering-Plough Corp. for the second quarter of 1999 are on track. Earnings per share of Schering Plough; Information on the sales of Claritin, an antihistamine product; Growth of the allergy-respiratory franchise of the company; Approval from the European Union's...

  • Schering-Plough Struggles to Land on Its Feet by 2005. Jarvis, Lisa // Chemical Market Reporter;12/1/2003, Vol. 264 Issue 19, p12 

    Reports on the efforts of pharmaceutical company Schering-Plough Corp. to recover from its financial difficulties resulting from drug production and marketing problems. Decline in the company's share prices; Analysis of the company's product share; Drug research on the impact of statins on the...

  • Fred Hassan. Strupp, Joe // njbiz;7/17/2006, Vol. 19 Issue 29, p15 

    The article profiles Fred Hassan, chairman and CEO of Schering-Plough. Hassan was the head of Pharmacia from 2001 to 2003 and lead the selling of the company to Pfizer for $60 billion. Hassan was acquired by Schering-Plough in 2003 during the time when the company was being repeatedly cited by...

  • Outlook for Pharma 2Q Earnings Mixed. Krause, Carey // Chemical Market Reporter;7/21/2003, Vol. 264 Issue 2, p12 

    Reports on the factors affecting the mixed forecast for the second quarter revenue and earnings growth for the large pharmaceutical companies in the United States in 2003. Effect of patent expiry at Schering-Plough Corp.; Implication of the completed merger between Pharmacia Inc. and Pfizer...

  • Schering-Plough's Rebetol approved to treat kids with hepatitis C. Martinez, Marialba // Caribbean Business;8/21/2003, Vol. 31 Issue 33, p14 

    Reports on the approval of Schering-Plough Corp.'s Rebetol, a combination hepatitis C virus treatment manufactured for global distribution in Las Piedras, for children three years and older. Competition of Intron franchise from Roche Holding AG's products; Other drugs manufactured by...

  • Pharma majors on 2Q upswing. Mirasol, Feliza // Chemical Market Reporter;7/31/2006, Vol. 270 Issue 4, p22 

    The article reports on the financial performances of pharmaceutical companies in the second quarter of 2006. An increase in earnings per share was posted by Merck from revenues from the company's vaccines portfolio. Schering-Plough also posted increases in earnings per share, driven by revenues...

  • Pharma Majors Post Strong Results.  // Chemical Market Reporter;10/30/2000, Vol. 258 Issue 18, p24 

    Reports on the financial results posted by some pharmaceutical companies during the third quarter of 2000. Revenues posted by Pfizer Inc.; Overall sales posted by Schering-Plough Corp.; Increase in sales posted by Merck & Co. Incorporated.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics